Welcome to our dedicated page for Pelthos Therapeutics SEC filings (Ticker: PTHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pelthos Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pelthos Therapeutics's regulatory disclosures and financial reporting.
Pelthos Therapeutics Inc. reported its fourth-quarter and full-year 2025 results, showing a rapid commercial ramp for its lead product ZELSUVMI and expansion of its dermatology portfolio. ZELSUVMI net product revenue reached $16.2 million from launch in July 2025 through December 31, including $9.1 million in the fourth quarter, while total 2025 revenue including licensing was $16.8 million. Prescribers wrote 8,948 ZELSUVMI units in 2025 from 2,712 unique prescribers, with dispensed units rising 129% quarter over quarter. Pelthos acquired FDA‑approved XEPI for impetigo in November 2025 and XEGLYZE for head lice in January 2026, positioning a three-product pediatric-focused infectious skin franchise. To fund growth, the company closed an $18.0 million private convertible notes financing in November 2025 and entered a $50.0 million senior secured term loan in January 2026, drawing $30.0 million. Cash was $18.0 million as of December 31, 2025. Despite this progress, Pelthos reported a 2025 net loss of $43.3 million, including a $21.7 million loss in the fourth quarter, driven by high selling and administrative expenses, a non-cash $15.0 million fair value loss on convertible debt, and ongoing investments in commercialization.
Pelthos Therapeutics Inc. files its annual report describing a small, dermatology-focused biopharma built around recently acquired and launched products. The company was effectively formed through a July 1, 2025 merger between Channel Therapeutics Corporation and LNHC, Inc., gaining ZELSUVMI, a Durham, North Carolina API facility, and NaV1.7 pain assets.
Pelthos now has three FDA-approved products: ZELSUVMI for molluscum contagiosum, launched in July 2025; XEPI for impetigo, acquired in November 2025 and expected to relaunch in late 2026; and XEGLYZE for head lice, acquired in December 2025 with launch expected in 2027. ZELSUVMI is the first at-home prescription therapy for molluscum contagiosum and is central to the company’s near-term revenue plans.
The report highlights financing steps, including a Venture Loan and Security Agreement providing a senior secured term loan facility of up to $50.0 million, of which $30.0 million was borrowed on January 12, 2026, and a July 1, 2025 PIPE financing that raised approximately $50.1 million through 50,100 shares of Series A Preferred Stock at $1,000 per share. As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately $6.7 million based on a $12.60 per share closing price, and 3,355,543 shares of common stock were outstanding as of March 11, 2026.
Management notes that the 2024 audit opinion contained a going concern qualification, while the 2025 opinion does not, but warns that failure to achieve sustainable revenues could still threaten the company’s ability to continue as a going concern. Extensive risk disclosures emphasize dependence on ZELSUVMI, challenges in building sales, marketing and market access, manufacturing and supply chain complexity around the NITRICIL nitric oxide platform, intense competition, regulatory and reimbursement uncertainty, data privacy obligations and thin trading liquidity in Pelthos common stock.
Pelthos Therapeutics Inc. received an amended Schedule 13G showing that investment adviser Ikarian Capital, LLC, together with its fund and certain managed accounts, beneficially owns 255,758 shares of common stock, or 8.4% of the company. This percentage is based on 3,235,543 shares outstanding as of November 7, 2025, as disclosed in a Form S-3. Ikarian Capital and its sole manager, Neil Shahrestani, may be deemed indirect beneficial owners through investment discretion, though each party includes customary disclaimers about beneficial ownership and group status. They certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Pelthos.
Pelthos Therapeutics Inc. is offering a resale prospectus covering up to 781,928 shares of its common stock. This includes 716,440 shares issuable upon conversion of secured convertible notes held by investors such as Ligand Pharmaceuticals, and 65,488 shares issuable upon exercise of warrants held by Horizon Technology Finance.
The shares may be sold from time to time by these selling stockholders using this shelf registration, and Pelthos will cover related registration expenses. Pelthos is a biopharmaceutical company commercializing ZELSUVMI, an FDA‑approved topical gel for molluscum contagiosum, launched in 2025.
The company highlights substantial risks, including a going concern qualification from its auditors and recurring net losses, with accumulated deficits of about $43.1 million as of September 30, 2025. Its ability to continue depends heavily on successfully commercializing ZELSUVMI and securing adequate capital.
Pelthos Therapeutics Inc. received an updated ownership report from investment entities 3i, LP, 3i Management LLC, and Maier Joshua Tarlow. They report beneficial ownership of 318,886 shares of common stock, representing 9.9% of the company’s outstanding shares based on 3,086,681 shares outstanding as of November 24, 2025.
The position includes 213,507 shares of common stock and 105,379 additional shares issuable from Series A convertible preferred stock and a senior secured convertible note, both subject to a 9.99% beneficial ownership blocker. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Pelthos Therapeutics.
Pelthos Therapeutics Inc. has filed a shelf registration to offer up to $200,000,000 of common stock, preferred stock, debt securities, warrants, rights and units from time to time. The company’s common stock trades on NYSE American under the symbol PTHS, with a public float of $39.2 million as of January 28, 2026, which limits primary equity sales under General Instruction I.B.6.
Pelthos is a biopharmaceutical company focused on commercializing ZELSUVMI, a berdazimer topical gel approved by the FDA in 2024 for molluscum contagiosum in patients one year and older. The business was formed through a 2025 merger involving Channel Therapeutics and LNHC, which holds rights to assets acquired from Novan.
The filing highlights substantial risks, including a going concern qualification on the 2024 and 2023 financial statements, an accumulated deficit of approximately $43.1 million as of September 30, 2025, continued net losses, and heavy dependence on the early-stage commercialization of ZELSUVMI. Additional risks span reimbursement, competition, manufacturing reliability, supply chain, third-party dependencies and intellectual property rights.
Pelthos Therapeutics Inc. entered into a venture loan and security agreement with Horizon Technology Finance, providing a senior secured term loan facility of up to $50.0 million. The company drew $30.0 million at closing, with up to an additional $20.0 million available upon achieving specified milestones, to support commercialization of ZELSUVMI, launches of Xepi and Xeglyze, and general corporate purposes.
The loans bear interest at the prime rate plus 3.75%, with the prime rate floored at 6.75%, and include an interest-only period through at least February 1, 2029, potentially extended to February 1, 2030 if trailing twelve-month consolidated net revenue reaches $75.0 million. The facility matures on January 31, 2031 and is secured by substantially all borrower assets. As part of the financing, Pelthos issued Horizon warrants to purchase 65,488 common shares at an exercise price of $27.49 per share, exercisable for five years.
Pelthos Therapeutics Inc. updated how it pays its non-employee directors, following a review by its compensation committee and approval by the board. Effective January 1, 2026, board members receive an annual cash retainer of $40,000, while the non-executive chairman receives $60,000. Committee retainers include $7,000 for audit committee members and $19,000 for the audit chair, $5,000 for compensation committee members and $15,000 for its chair, and $4,000 for nominating and corporate governance committee members and $12,000 for its chair.
The company notes that non-employee directors may receive an initial equity grant under its 2023 Equity Incentive Plan when they first join the board, at the board’s discretion, but they do not receive annual equity awards for ongoing service. Pelthos also furnished, but did not file, an investor presentation on its website as of January 12, 2026, highlighting that this information is provided under Regulation FD and is not incorporated into other securities filings unless specifically referenced.
Pelthos Therapeutics Inc. entered into an Asset Purchase Agreement with Hatchtech Pty Ltd under which Pelthos bought all rights to the Xeglyze Product, a head lice treatment using Abametapir, and related intellectual property, regulatory materials, and tangible assets. The aggregate purchase price is $1,800,000, consisting of a $450,000 down payment made on November 20, 2025 and a $1,350,000 cash payment made on December 23, 2025. Pelthos obtained contractual rights to claw back up to 100% of the purchase price for certain seller defaults and if closing had not occurred by December 29, 2025. The transaction was consummated on the agreed closing date, and Pelthos plans to issue a press release announcing the closing.